LAS VEGAS, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapeutics that address Cytokine Release Syndrome (CRS) caused by viral infections like COVID-19 and others. Over the two pandemic years, more than 540 million people across the world contracted COVID-19 and 6.3 million... Read More

LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which are mood altering but non-hallucinogenic. Recently, Gb Sciences received positive preclinical results supporting the efficacy of its... Read More

Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Food and Chemical Toxicology that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation. Finding Cannabis compounds with anti-inflammatory... Read More

Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (GBLX-OTC), a leading plant-inspired, biopharmaceutical research and drug development company, is demonstrating their AI-enabled drug discovery engines' ability to identify novel plant-inspired pharmaceuticals today at the 10th Annual Drug Discovery Strategic Summit in San Francisco, California. In her session entitled " The Use of an AI-enabled Drug... Read More

Gb Sciences, Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS' proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC... Read More

Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, is demonstrating the potential efficacy of their proprietary cannabis-inspired mixtures today at the Canna Pharma 2022 Conference in San Diego, California. Dr. Small-Howard explains Gb Sciences' novel process for developing disease-specific, cannabinoid... Read More

Gb Sciences, Inc . (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Frontiers in Pharmacology that demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson's disease (PD). There is a great clinical need for improved therapeutics, and the market for Parkinson's... Read More

Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, describes their progress towards achieving significant milestones in their drug development pipeline in an article published in the journal Pharma's Almanac today at https://www.pharmasalmanac.com/articles/unlocking-the-therapeutic-potential-of-plant-inspired-minimum-essential-mixtures . "Gb Sciences is... Read More

Gb Sciences is a plant-inspired, biopharmaceutical research and drug development company that began building its proprietary digital research and analytics platform long before the pandemic sparked a digital transformation. According to a study by Deloitte , biopharma lagged behind other industries in digital transformation. Eighty percent of survey respondents (including 150 executives from large biopharma companies) said... Read More

Gb Sciences is a plant-inspired, biopharmaceutical research and drug development company that began building its proprietary digital research and analytics platform long before the pandemic sparked a digital transformation. According to a study by Deloitte , biopharma lagged behind other industries in digital transformation. Eighty percent of survey respondents (including 150 executives from large biopharma companies) said... Read More

Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), presents a Keynote Address today at this year's NeuroForum Summit on the theme of "Emerging Perspectives in Neurology and Brain Research". Dr. Small-Howard explains Gb Sciences' multicomponent, plant-inspired therapeutics may be an attractive alternative for Parkinson's patients in the future, after their company has secured US FDA... Read More

Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, discusses the current and future importance of its proprietary drug discovery platform PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) at the 2nd ALCOR Drug Discovery Platform Summit today. " Demonstrating the capabilities of our novel drug... Read More

Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, spoke today at Europe's leading pain therapeutics conference, SMi's 22nd Annual Pain Therapeutics Conference in London. Dr. Small-Howard's presentation can be viewed here in its entirety . "Gb Sciences' plant-inspired therapeutics provide a promising new option... Read More

Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, announces that FHI Clinical Inc. will consult on Gb Sciences' go-to-market strategy for its COVID-19-related, anti-inflammatory therapeutics and, ultimately, write Gb Sciences' draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations. FHI Clinical has... Read More

Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, has selected the University of Lethbridge in Canada to complete a dose range study of Gb Sciences' patent-protected formulations in a rodent model of Parkinson's disease (PD). Gb Sciences plans on filing an Investigational New Drug Application to begin first-in-human clinical trials as early as next year. As the... Read More

Gb Sciences , Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired, biopharmaceutical research and development company, announces that their sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was published in the International Journal of Pharmaceutics on March 25. For the Gb Sciences-sponsored study, researchers at the... Read More

LAS VEGAS, March 16, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to shareholders from President, Chief Science Officer, and Director Dr. Andrea Small-Howard and Chairman and CEO John Poss, summarizing key developments from 2021 and providing strategic plans for 2022. Full text of the shareholder... Read More

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has been issued a new patent today by the U.S. Patent and Trademark Office (USPTO) for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease. Gb Sciences' newly issued patent also covers the use of these receptor-targeted formulations for the treatment of... Read More

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry. "This is a landmark event for Gb Sciences," said Chairman and CEO John Poss. "We have emerged from this sale as a pure-play biopharmaceutical research and development company. With an improved... Read More

Gb Sciences , a plant-based research and biopharma technology company, has reported positive results from a study of its potential treatment for cytokine release syndrome (CRS), one of the most dangerous complications of COVID-19. With reports of the arrival of the Omicron variant of the coronavirus in multiple countries, the Gb Sciences team plans to move quickly through the development stages for this novel CRS therapy.... Read More

Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company Gb Sciences has taken innovative steps to speed up the process and is developing key relationships to further advance the clinical development of its novel, plant-inspired therapies for the prescription drug market. To expedite its discovery processes, Gb Sciences utilizes... Read More

Gb Sciences , Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has initiated new preclinical studies at the National Research Council of Canada ("NRC") through GbS' Canadian subsidiary, GbS Global Biopharma, Inc. The NRC will test GbS' proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending... Read More

Gb Sciences, Inc. (OTCQB: GBLX) received positive proof-of-concept data from a human immune cell model supporting their proprietary cannabinoid-containing complex mixtures (CCCM) designed for the suppression of COVID-related cytokine release syndromes (CRS) while preserving key anti-viral immune responses. Based on this new positive proof-of-concept data, Gb Sciences converted their provisional patent application entitled,... Read More

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical development company, today announced that their President and Chief Science Officer, Dr. Andrea Small-Howard, will deliver their company presentation during the Healthcare & Biotech Track at the H.C. Wainwright 23rd Annual Global Investment Conference , to be held virtually from September 13 to September 15, 2021. Dr. Small-Howard will provide an... Read More

Gb Sciences (OTCQB:GBLX), a plant-based research and biopharmaceutical drug development company, today announced that it will be presenting at the SNN Network Summer Virtual Event 2021 on Wednesday, August 18 th at 3:00 PM EST. Dr. Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences will be hosting the presentation and answering questions from investors. To access the live presentation, please... Read More

GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain from mixtures of compounds identified within Kava and other plants from within the Piper family. GB Sciences, Inc. (OTCQB:GBLX) announced the completion of a data science study identifying proprietary therapeutic mixtures from within the... Read More

Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants. GB Sciences (OTCQB:GBLX) is leading the way in cutting-edge biopharmaceutical research with its novel AI-accelerated drug discovery platform-PhAROS™ - Phytomedical Analytics for Research Optimization at Scale. The PhAROS platform is a... Read More

The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc. Dr. Andrea Small-Howard has been promoted to the role of President of GB Sciences, Inc. Dr. Small-Howard will also retain her roles as Chief Science Officer and member of the board of directors. Joining GB Sciences in June of 2014 as the Chief Science Officer and a founding member of the board of directors, Dr. Small-Howard has made considerable... Read More

Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM). GB Sciences, Inc. (OTCQB:GBLX) and Purisys, LLC , the global industry leader in ultra-high purity, pharmaceutical grade cannabinoid supply, today announced that GB Sciences has selected... Read More

GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability allows researchers to reduce the time and money required for novel, plant-based combination drugs to get to market. This... Read More

GB Sciences , Inc. (OTCQB:GBLX) and its Spanish research partners at the Universidad de Sevilla (USE) are pleased to announce the publication of a new scientific paper describing the creation of terpene-containing nanoparticles for use in the treatment of pain. In the journal Industrial Crops and Products , this study entitled... Read More